CDR813 / CDR-Life - LARVOL DELTA

Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01 (ESMO 2024) - "Here we describe CDR813 an antibody fragment-based T cell engager which bivalently binds to an HLA-A2-restricted PRAME peptide on tumors. CDR813 was preclinically characterized for selective killing of PRAME/HLA-A*02 positive human cancer cells versus a panel of different PRAME-negative/HLA-A*02-positive human cell lines in co-cultures with PBMCs... Considering the in vitro potency, specificity profile, and drug-like biophysical properties, this clinical candidate holds the potential to exhibit best-in-class characteristics in a clinical setting."

IO biomarker • Endometrial Cancer • Melanoma • Oncology • Solid Tumor • HLA-A • PRAME

CDR-Life Announces Pipeline Progress of M-gager Programs for Treatment of Solid Tumors (Businesswire) - "The first patient was dosed with CDR404, a novel, bispecific and bivalent antibody fragment-based T cell engager (TCE) targeting MAGE-A4, an intracellular cancer-specific protein that is cleaved into smaller peptide fragments and presented on HLA-A*02:01 molecules at the surface of cancer cells....CDR-Life has identified and characterized an antibody fragment-based TCE as a clinical candidate targeting PRAME called CDR813. This TCE binds potently and bivalently to an HLA-A*02-restricted PRAME peptide on the surface of cancer cells. Pre-clinical studies have shown that CDR813 has very favorable pharmacological and manufacturability properties with best-in-class potential for the clinic."

Preclinical • Trial status • Oncology • Solid Tumor • Squamous Cell Carcinoma

CDR-Life Announces Pipeline Expansion of Highly Tumor-Targeted T Cell Engagers (Businesswire) - "CDR-Life Inc. today announced an expansion of its pipeline of novel T cell engagers (TCE) with the addition of CDR813 and CDR505. CDR813 is a highly potent and selective TCE candidate targeting tumors expressing PRAME (preferentially expressed antigen in melanoma) in HLA-A*02:01 patients....While most TCE programs target the HLA-A02 haplotype, CDR505 targets KK-LC-1/HLA-A*01, expanding the potential of TCEs to benefit a large patient population with high unmet need."

New molecule • Melanoma • Oncology • Skin Cancer • Solid Tumor